Justin Benabdallah, MD
Urology · Washington, DCNPI 1134419328
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Olympus America Inc. accounts for 60.3% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $314, more than ten times the $18 reported in 2019. That places this record below the midpoint for urology clinicians in DC, where the typical reported total is $1,957.
Across 11 payments — averaging $54.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$364
- Urogen Pharma, Inc.$170
- Boston Scientific$25
- Ambu Inc.$25
- Photocure Inc$20
What the payments were for
- Food & beverage$603100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 6 | $364 |
| Urogen Pharma, Inc. | 2 | $170 |
| Boston Scientific | 1 | $25 |
| Ambu Inc. | 1 | $25 |
| Photocure Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$603 in reported general payments places this provider in the 35th percentile of 47 urology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 36 | $42,376 |
| Tamsulosin Hcl | 265 | $6,110 |
| Tadalafil | 28 | $4,970 |
| Silodosin | 26 | $3,318 |
| Finasteride | 112 | $2,072 |
| Dutasteride | 16 | $1,289 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 48 | $1,286 |
| CefuroximeCefuroxime Axetil | 18 | $170 |
| Sildenafil Citrate | 23 | $119 |
Paid to pharmacies, not to this prescriber.
Other urology in Washington
- Armine SmithWashington$58K
- Nathan ShawWashington$54K
- Lambros StamatakisWashington$39K
- Patrick MufarrijWashington$31K
- Ryan HankinsWashington$29K
- Adam MetwalliWashington$27K
- Michael WhalenWashington$17K
- Pamela ColemanWashington$14K
- Leslie DeaneWashington$13K
- Jason EngelWashington$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.